bioRxiv Science⌕ Search

Biology subjects

Polonsky, K.

Publications and source records attributed to Polonsky, K..

5 recordsLinked to original sources

A deep-learning-based score to evaluate multiple sequence alignments

Multiple sequence alignment (MSA) inference is a central task in molecular evolution and comparative genomics, and the reliability of downstream analyses, including phylogenetic inference, depends critically on alignment quality. Despite this importance, most widely used MSA methods optimize the sum-of-pairs (SP) score, and relatively little attention has been paid to whether this objective function accurately reflects alignment accuracy. Here, we evaluate the performance of the SP score using simulated and empirical benchmark alignments. For each dataset, we compare alternative MSAs derived from the same unaligned sequences and quantify the relationship between their SP scores and their distances from a reference alignment. We show that the alignment with the optimal SP score often does not correspond to the most accurate alignment. To address this limitation, we develop deep-learning-based scoring functions that integrate a collection of MSA features. We first introduce Model 1, a regression model that predicts the distance of a given MSA from the reference alignment. Across simulated and empirical datasets, this learned score correlates more strongly with true alignment accuracy than the SP score. However, Model 1 is less effective at identifying the best alignment among alternatives. We therefore develop Model 2, which takes as input a set of alternative MSAs generated from the same sequences and predicts their relative ranking. Model 2 more accurately identifies the top-ranking MSA than the SP score, Model 1, and several widely used alignment programs. Using simulations, we show that selecting MSAs based on our approach leads to more accurate phylogenetic reconstructions.

bioinformatics↗

Decoy Antibodies Block Extracellular HSP70, Prevent Self Signaling and Inhibit Melanoma Cell Survival

Melanoma cells actively secrete melanosomes-large, extracellular vesicles (EVs) enriched with oncogenic factors that reprogram the tumor microenvironment, enhance self-signaling, and promote tumor growth. Despite their abundance and immunogenic potential, humoral responses to melanoma-derived melanosomes remain unexplored. Here, we identify a novel immune surveillance mechanism in which melanosome-elicited decoy antibodies target melanoma-derived melanosomes by binding to the extracellular form of heat shock protein 70 (HSP70), a chaperone broadly implicated in cancer cell survival and stress adaptation. Anti-HSP70 decoy antibodies potently and effector-independently inhibit growth and survival of both murine and human melanoma cells and suppress key transcriptional programs involved in proliferation, cytoskeletal dynamics, and metabolism. In a preclinical B16 melanoma model, prophylactic administration of decoy monoclonal antibodies Mel322-34 and Mel321-35 conferred significant survival benefits of 27% and 48%, respectively. Strikingly, anti-HSP70 antibodies were enriched in the sera of melanoma patients achieving complete responses to immune checkpoint blockade, in contrast to non-responders with progressive disease. Collectively, our findings uncover a novel EV-antibody axis as a promising avenue to block cancer-promoting signaling pathways. Decoy autoantibodies targeting the extracellular form of HSP70 advance the understanding of tumor-intrinsic vulnerability and promote biomarker-driven immunotherapy in melanoma.

immunology↗

Potent Neutralization by Antibodies Targeting the Mpox A28 Protein

Mpox is the most pathogenic Poxvirus in circulation. While several antigens have been identified as targets for neutralizing antibodies, many proteins remain unexplored. We isolated and characterized four monoclonal antibodies (mAbs) targeting the Mpox A28 (OPG153), a virulence factor present on mature Mpox virions. The antibodies were isolated from convalescent individuals, alongside 14 additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralized Mpox and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High resolution crystal structures of Anti-A28 mAbs 10M2146 and 8M2110 in complex with VACV A26 revealed two proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 attenuated disease in infected mice. Moreover, immunization with A28 elicited antigen-specific B cells and robust neutralizing antibody responses and provided complete protection against lethal VACV challenge. These findings support Mpox A28 as a promising target for the induction of neutralizing antibodies and antiviral interventions.

immunology↗

Evaluation of the Ability of AlphaFold to Predict the Three-Dimensional Structures of Antibodies and Epitopes

Being able to accurately predict the three-dimensional structure of an antibody can facilitate fast and precise antibody characterization and epitope prediction, with important diagnostic and clinical implications. In the current study, we evaluate the ability of AlphaFold to predict the structures of 222 recently published, non-redundant, high resolution Fab heavy and light chain structures of antibodies from different species (human, Macaca mulatta, mouse, rabbit, rat) directed against different antigens. Our analysis reveals that while the overall prediction quality of antibody chains is in line with the results available in CASP14, other antibody regions like the complementarity-determining regions (CDRs) of the heavy chain, which are prone to higher genetic variation, generate a less accurate prediction. Moreover, we discovered that AlphaFold often mis-predicts the bending angles between the variable and constant domains within a Fab. To evaluate the ability of AlphaFold to model antibody:antigen interactions based only on sequence, we used AlphaFold-multimer in combination with ZDOCK docking to predict the structures of 26 known antibody:antigen complexes. ZDOCK succeeded in predicting 11, and AlphaFold only two, out of 26 models with medium or high accuracy, with significant deviations in the docking contacts predicted in the rest of the molecules. In summary, our study provides important information about the abilities and limitations of using AlphaFold to predict antibody:antigen interactions and suggests areas for possible improvement. Key PointsO_LIAlphaFold was used to predict 222 new 3D hi-res atomic structures of Ab chains. C_LIO_LILow accuracy was observed in the prediction of HC-CDR3 and the elbow angles. C_LIO_LIPredicting Ab-Ag complexes and epitope mapping using AlphaFold-Multimer was limited. C_LI

immunology↗

Multi-Clonal Live SARS-CoV-2 In Vitro Neutralization by Antibodies Isolated from Severe COVID-19 Convalescent Donors

The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of COVID-19 and protective immunity. To understand the differences between antibody responses in mild versus severe cases of COVID-19, we analyzed the B cell responses in patients 1.5 months post SARS-CoV-2 infection. Severe and not mild infection correlated with high titers of IgG against Spike receptor binding domain (RBD) that were capable of viral inhibition. B cell receptor (BCR) sequencing revealed two VH genes, VH3-38 and VH3-53, that were enriched during severe infection. Of the 22 antibodies cloned from two severe donors, six exhibited potent neutralization against live SARS-CoV-2, and inhibited syncytia formation. Using peptide libraries, competition ELISA and RBD mutagenesis, we mapped the epitopes of the neutralizing antibodies (nAbs) to three different sites on the Spike. Finally, we used combinations of nAbs targeting different immune-sites to efficiently block SARS-CoV-2 infection. Analysis of 49 healthy BCR repertoires revealed that the nAbs germline VHJH precursors comprise up to 2.7% of all VHJHs. We demonstrate that severe COVID-19 is associated with unique BCR signatures and multi-clonal neutralizing responses that are relatively frequent in the population. Moreover, our data support the use of combination antibody therapy to prevent and treat COVID-19.

immunology↗